Copay Assistance – Good For Patients, Bad For Prices
Peter Bach and I have an essay in the Annals of Internal Medicine laying out some of the problems with pharmaceutical funded copay assistance programs. Check it out.
Similar Posts
Watch Out Hospitals: Medicare’s Planning to Punish You if You Misbehave
ByadminIt used to be that hospitals billed Medicare for the services they provided, and Medicare – I know this is crazy! – simply paid the bills. Those days are rapidly receding into history. Soon, a significant chunk of hospital revenue will be at risk, under a series of Medicare pay-for-performance programs. The idea behind P4P…
Why It's Not Time For Health Care Rationing
ByadminIn the last few years, the U.S. health care system has seemingly been gripped by “back to the nineties” fever. Back then, we had a Democratic president working to reform the health care system. Experts from across this system were promoting the importance of controlling health care costs; the growth of health care expenditures even…
The Hepatitis C Epidemic in One Picture
ByadminHepatitis C has been in the news lately, because of amazing (and amazingly expensive) new treatments that promise to cure their life-threatening illness. While we ought to debate the expense of these treatments, we should also remind ourselves of how much we’ve been spending caring for patients with advanced disease. Here’s a picture showing the…
What Are the Biggest Forces Driving Change in the Healthcare Marketplace?
ByadminHere is what one group of experts thought:
Are Medicare Prescription Benefits Too Stingy?
ByadminThe bill she received in the mail revealed a staggering figure — $9,225 for one infusion of Avastin, a chemotherapy drug. And she would need many more such infusions. Fortunately, the dollar amount is what medical experts call a “charge,” which in normal marketplaces refers to the amount a provider expects for the good or…